Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2.

Pre-clinical and on-going trials have indicated the advantage of using metformin as an anticancer drug alone or in combination with other chemotherapeutics for the treatment of patients with breast cancer. However, the mechanisms by which metformin attenuates tumorigenesis remain to be further elucidated. The present study investigated the anticancer effects of metformin in breast cancer and identified potential molecular targets of metformin using western blotting and immunohistochemical analysis. Metformin significantly decreased tumor cell proliferation in vitro and suppressed tumor growth in vivo. Moreover, it induced the activation of AMP-induced protein kinase and suppression of phosphorylated-eukaryotic translation initiation factor 4E-binding protein 1 (p-4E-BP1), a downstream effector of the mTOR signaling pathway, and decreased cyclin D1 levels in in vitro and in vivo experimental models. Additionally, metformin inhibited cyclooxygenase (COX)-2 expression. Clinically, high expression levels of COX-2 and p-4E-BP1 in tissues of patients with breast cancer were significantly associated with enhanced lymphatic metastasis and distant metastasis. Thus, the current data suggested that metformin may have potential value as a synergistic therapy targeting both the COX-2 and mTOR signaling pathways. Copyright: © Shi et al.

Introduction

Breast cancer is the most common malignancy in women and the most common cause of cancer-associated death among women worldwide (1). Advances in early detection and cancer therapy have led to a reduction in the incidence of breast cancer, and breast cancer-associated deaths have decreased by ~2% in the past decade (2). However, the prognosis of patients varies greatly and is affected by numerous factors, including tumor type, stage, treatment and geographical location; for example, prognosis is better among patients in Western countries than among those in developing countries (3). Furthermore, a higher stage at diagnosis is associated with a poorer prognosis; stage 0 ductal carcinoma in situ has an excellent prognosis with a 10-year survival rate of ~98%, while stage IV metastatic cancer has a poor prognosis with a 10-year survival rate of <10% (4). This discrepancy poses a substantial clinical challenge. Thus, it is necessary to identify novel molecular targets and drugs that will strengthen early intervention and effective therapeutic strategies.

Several studies have indicated that patients with type 2 diabetes mellitus (DM) have an increased risk for the development of several types of cancer, including breast cancer (5–11). Metformin is a first-line drug for type 2 DM, and numerous studies have demonstrated that it is associated with a lower risk of breast cancer in patients with type 2 DM (12–15). Metformin inhibits the proliferation and colony formation of cancer cells by inducing cell cycle arrest and apoptosis by modulating the expression levels of proteins that regulate the G1-S cell cycle transition, including cyclin D1, cyclin E1 and E2F transcription factor 1 (12,16–18). The AMP kinase (AMPK) regulatory system is one of the main targets of metformin therapy (19). The activation of AMPK regulates tumor cell survival and tumor growth through inhibition of the mTOR and fatty acid synthesis signaling pathways, and it also stimulates the apoptotic pathway (p53/p21 axis) (14,20,21). However, the precise molecular mechanisms of metformin in breast cancer remain to be fully elucidated.

Cyclooxygenase-2 (COX-2) is expressed in numerous types of solid tumor tissues and cells, and serves a key role in the development of breast cancer (22,23). COX-2 expression is upregulated in ~50% of breast cancer cases, and high COX-2 expression is significantly associated with a poor clinical outcome (24–27). COX-2 is associated with increased proliferation and angiogenesis in human breast cancer (28,29). Furthermore, COX-2 increases the production of prostaglandin E2 (PGE2), which stimulates breast cancer progression and bone metastasis (30–32). Therefore, COX-2 inhibitors may have a role in the prevention and treatment of breast cancer, and may have value as novel biomarkers to stratify breast cancer risk in women with atypia (33). Non-steroidal anti-inflammatory drugs (NSAIDs), particularly the highly selective COX-2 inhibitors, have been shown experimentally to stimulate apoptosis and inhibit angiogenesis, two mechanisms that can counteract tumor growth, progression and metastasis (34). In addition to NSAIDs, administration of metformin can prevent the increase in COX-2 expression induced by dehydroepiandrosterone and enhance the activation of phosphorylated (p)-AMPKa expression in embryonic ovarian disorders (35,36). While the aforementioned studies have confirmed an association of high COX-2 expression with highly aggressive tumors and have emphasized the anticancer action of metformin in breast cancer, the underlying mechanisms remain unclear.

The present study provided preliminary evidence that metformin inhibited breast cancer cell proliferation via the well known AMPK/mTOR signaling pathway and the novel AMPK/COX-2 signaling pathway.

Materials and methods

Clinical samples

Between January 2016 and December 2018, 63 patients with invasive breast cancer that underwent curative surgical resection at the Changhai Hospital (Shanghai, China) and Kunshan Hospital (Jiangsu, China) were enrolled in the present study. Tumor and adjacent normal tissues from patients with breast cancer were obtained and the expression levels of AMPK/COX-2/mTOR signaling proteins were analyzed. Non-tumor specimens were ≥1.5 cm from the tumor margins. All 63 patients were female and aged between 38 and 78 years (mean age ± SD, 50.5±6.7 years). A total of 29 (46.0%) and 34 (54.0%) patients were aged <50 years and >50 years, respectively. The tumors were staged following the tumor-node-metastasis (TNM) staging system of the International Union Against Cancer (37). A total of 53 (84.1%) tumors were categorized as stage I–II and 10 (15.9%) tumors as stages III–IV. None of the patients received preoperative chemotherapy and/or radiation therapy. Freshly resected tissues from patients with breast cancer were immediately snap-frozen in liquid nitrogen. All the clinical specimens were obtained with written informed consent, and the Institutional Review Boards of the Affiliated Kunshan First People's Hospital of Jiangsu University and Changhai Hospital approved the use of all tissues and clinical information (approval no. CHEC2014-098).

Reagents and antibodies

Metformin (cat. no. 1115-70-4) was purchased from Sangon Biotech Co., Ltd. Antibodies against p-AMPKα (Thr-172 or D4D6D; cat. no. 50081), AMPKα (D5A2; cat. no. 5831), p-eukaryotic translation initiation factor 4E-binding protein 1 (p-4E-BP1; Thr-37/46; cat. no. 2855), 4E-BP1 (53H11; cat. no. 9644), COX-2 (D5H5; cat. no. 4842) and Cyclin D1 (E3P5S; cat. no. 55506) were purchased from Cell Signaling Technology, Inc. Anti-proliferating cell nuclear antigen (PCNA) antibody (EPR3821; cat. no. ab92552) and anti-PGE2 antibody (cat. no. ab45295) were obtained from Abcam. Anti-β-actin (C4; cat. no. sc-47778) was obtained from Santa Cruz Biotechnology, Inc.

Cell culture

The breast cancer MCF-7 and 4T1 cell lines were purchased from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. Both cell lines were grown in DMEM (Invitrogen; Thermo Fisher Scientific, Inc.) with 10% FBS (Invitrogen; Thermo Fisher Scientific, Inc.). The cell lines were kept at 37°C in a humidified incubator with 5% CO2.

MTT assay

The MTT assay was used to assess the anti-proliferative effects of metformin in MCF-7 and 4T1 cells. In recent years of breast cancer research, the dosage range of metformin has been 1–50 mM, and the highest dosage can reach 100 mM (38,39). It has been reported that metformin can induce the AMPK signaling pathway in the dose range of 10–20 mM, thereby increasing apoptosis (40). Therefore, metformin with the dose range of 20–50 mM was selected to study its antitumor mechanism. Exponentially growing cells were trypsinized, counted and plated at 5×103 cells/well in 96-well plates. After 24 h, cells were treated with 0, 20 or 50 mM metformin for 24, 48, 96 or 144 h. Thereafter, the medium was changed, and the cells were incubated with 10 µl MTT (Sigma-Aldrich; Merck KGaA; 5 mg/ml) at 37°C for 4 h before each test. The supernatant was then carefully discarded, and 150 µl DMSO (Sigma-Aldrich; Merck KGaA; cat. no. D2650) was added to dissolve the precipitate. Absorbance at 490 nm (A570) for the experimental group and DMSO (control) was measured using a microplate reader (KHB ST-360; Shanghai Kehua Bio-Engineering Co., Ltd.). Finally, actual absorbance was calculated using the following formula: Actual absorbance = absorbance of treated cultures-absorbance of DMSO. To ensure consistency, the experiment was repeated three times in all cases.

Colony formation assay

For each treatment, cells were plated at 1×103 cells/well in 6-well plates in triplicate. After the cells were attached, the cells were treated with 0, 20 or 50 mM metformin for 14 days and then fixed in −20°C precooled methanol/acetone (1:1) solution for 10 min. After fixation, the cells were stained using crystal violet (Sigma-Aldrich; Merck KGaA; cat. no. C0775) for 1 min at room temperature. The colonies with ≥50 cells were manually counted under an inverted light microscope (magnification, ×400; CX31; Olympus Corporation). The number of colonies for breast cancer cells were calculated as: Colonies/500×100.

Cell cycle analysis

The cells were seeded in 6-well plates (2×105 cells/well) overnight and then exposed to 0, 20 and 50 mM metformin for another 48 h. Exponentially growing cells were trypsinized and precipitated overnight with 70% ethanol at 4°C. Next, the cells were washed, resuspended in fresh PBS containing propidium iodide with 0.1% Triton X-100 (Sigma-Aldrich; Merck KGaA) and RNase A (Beyotime Institute of Biotechnology), and then the reaction was further incubated for 30 min in the dark at 37°C. Cell cycle distribution was determined using the BD FACSAria™ III Cell Sorting system (Becton, Dickinson and Company) and analyzed using the ModFit LT software (version 5.0; Becton, Dickinson and Company).

Xenografts

Subcutaneous xenograft mouse models were used to estimate the antitumor efficacy of metformin. A total of 10 female athymic BALB/c nude mice (4-week-old; average weight, 20 g) were kept under pathogen-free conditions. All animals were housed in metabolic cages (dimensions, 500×360×200 mm), with 2 or 3 mice per cage. During the experimental procedure, nude mice were kept at a temperature of 23±2°C, humidity of 50±10% and light-controlled environment (12/12-h light/dark cycle). The mice were free to drink and eat. The litter was changed every other day. After completing the experiment, the mice were sacrificed by cervical dislocation after anesthesia with an intraperitoneal injection of 0.6% sodium pentobarbital (40 mg/kg). Death was carefully verified by monitoring cessation of corneal reflex, heartbeat and breathing. 4T1 cells (1×106 cells/mouse) in PBS were injected subcutaneously into the right upper flank of the mice. When the mean tumor diameter was ~4 mm, the animals were randomly assigned to two groups (control group and metformin treatment group, n=5 in each group). Metformin (250 mg/kg) was injected intraperitoneally once daily. The control group was treated similarly but with sterile saline solution instead of metformin (0.9% NaCl in ultrapure water). Tumor long/short diameter was measured every 2–3 days. All animals were sacrificed after the end of the experiment at day 14, and the tumors were harvested and weighed. The length of tumor was measured by caliper, and tumor volume (mm3) was estimated by the formula V = 0.52 × length × width × depth. Humane endpoint criteria were defined as follows: i) body weight loss persisted beyond 20% of predose weight; ii) tumor size exceeding 3,000 mm3; and iii) anorexia or loss of mobility. All animal experimental protocols were reviewed and approved by the Animal Ethics Committee of the Second Military Medical University (Shanghai, China).

Western blot analysis

Standard western blotting was performed as previously described (41). In short, whole-cell lysates were prepared from 4T1 and MCF7 cells at 0, 24, 48 and 72 h after the addition of metformin (0, 20 and 50 mM). Breast cancer cells were lysed using RIPA lysis buffer (Sangon Biotech Co., Ltd.). Total protein concentration was quantified using the BCA method. The protein samples (30 µg/lane) were electrophoresed via 10% SDS-PAGE and then transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories, Inc.). After being blocked with 1% BSA (Sigma-Aldrich; Merck KGaA) for at least 2 h at room temperature, the membranes were incubated overnight with the aforementioned primary antibodies for 10–12 h at 4°C (p-AMPKα, AMPKα, β-actin, cyclin D1, p-4E-BP1, 4E-BP1, PGE2 and COX-2; all 1:1,000) and then incubated for 2 h at room temperature with HRP-conjugated anti-rabbit (1:1,000; cat. no. ab205718; Abcam) and anti-mouse (1:1,000; cat. no. ab205719; Abcam) secondary antibodies. Finally, the membranes were washed three times and immunoreactive proteins were detected using an enhanced chemiluminescence kit (Amersham; Cytiva) and analyzed using Quantity One software version 4.6 (Bio-Rad Laboratories, Inc.).

Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC)

Tumor and adjacent normal tissues (confirmed as normal by the pathology department) were fixed in 10% formalin for 24 h at room temperature, embedded in paraffin and cut into 4-µm-thick sections for IHC or H&E. IHC and H&E staining were performed using the Histostain™ kit (Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. Briefly, the tissue slides were deparaffinized in xylene (three washes for 5 min each) and graded ethanol dilution series (100, 95, 70 and 50% ethanol, each washed twice for 10 min each) and washed in deionized water (two washes for 5 min each). The slides were then fixed in 10% paraformaldehyde for 10 min at room temperature and subsequently rinsed in PBS. Fixed samples were incubated with 3% H2O2 solution at room temperature for 10 min followed by washing with PBS three times. Antigen retrieval was achieved by boiling slides in 0.01 M citrate buffer, pH 6.0, for 10 min, cooling to room temperature and rinsing three times with PBS. Tissue sections were incubated with serum blocking solution provided in the aforementioned kit for 10 min at room temperature, followed by incubation with primary antibody against p-AMPKα (1:100), COX-2 (1:100), cyclin D1 (1:100), PCNA (1:100) and p-4E-BP1 (1:200) at room temperature for 1 h. After washing off the primary antibody in PBS, sections were incubated with biotinylated broad-spectrum secondary antibody (Histostain®-Plus 3rd Gen IHC Detection kit; Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 85-903) at room temperature for 10 min. At the end of incubation, the sections were washed again in PBS, and then incubated for a further 10 min at room temperature in the presence of streptavidin-enzyme conjugate. After washing with PBS, sections were incubated with substrate-chromogen mixture at room temperature for 5 min and washed with PBS again. Hematoxylin was used to stain slices for 1 min at room temperature, followed by a rinse with tap water. Sections were finally mounted and dried until observation. Tissue samples were evaluated and blindly scored by two independent investigators using a light microscope (Olympus Corporation). The criteria for scoring were as follows: 0, absence of positive staining; 1, weak staining intensity; 2, moderate staining intensity; and 3, strong staining intensity. The percentage of positively stained cells was obtained in at least five different visual fields at ×400 magnification for each section, and assigned a value between 0 and 100%. The final score of immunoreactivity was obtained by multiplying the staining intensity score by the percentage of positive tumor cells in each case. The scores ranged from 0 (0% of cells stained) to 3 (100% strong staining).

Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA from cells was isolated using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). First, first-strand cDNA was reverse transcribed from 1 µg total RNA using M-MLV reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 10 min according to the manufacturer's instructions of the PrimeScript RT reagent kit (Takara Bio, Inc.). qPCR was performed on the 7500HT Fast Real-Time PCR machine (Applied Biosystems; Thermo Fisher Scientific, Inc.) using SYBR-Green Master mix (Takara Bio, Inc.). The thermocycling conditions were as follows: Enzyme activation at 95°C for 30 sec; 30 cycles of denaturation and annealing at 95°C for 5 sec and 55°C for 20 sec, respectively; hold at 4°C. Relative gene expression was determined using the SYBR Green Master Mix (Takara Bio, Inc.). GAPDH was used for internal expression normalization. Relative expression levels were normalized to endogenous controls and were expressed as 2−ΔΔCq (42). Each sample was analyzed in triplicates for the target genes and internal control gene. The primers for qPCR were as follows: COX-2 forward, 5′-ATCATTCACCAGGCAAATTGC-3′ and reverse, 5′-GGCTTCAGCATAAAGCGTTTG-3′; and GAPDH forward, 5′-TGTTGCCATCAATGACCCCTT-3′; and reverse, 5′-CTCCACGACGTACTCAGCG-3′.

Luciferase reporter assay

Breast cancer cells were seeded in 24-well plates and grown to 70–80% confluence. The cells were transfected with the human COX-2 promoter fragments (a generous gift from Professor Qi Li, Shuguang Hospital, Shanghai, China) using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO2 for 6 h, which were inserted into the pGL3 plasmid (Promega Corporation; cat. no. E1761) and monitor plasmid pRL-TK (Promega Corporation; cat. no. E2241). These cells were treated with 0, 20 or 50 mM metformin. After 48 h of treatment, cells were collected, washed and harvested to measure the firefly and Renilla luciferase activities using the Dual-Glo™ Luciferase reporter assay system (Promega Corporation; cat. no. E2920) according to the manufacturer's instructions. Luciferase activity was normalized to that of the co-transfected pRL-TK plasmid. All experiments were performed at least twice in triplicates.

Statistical analysis

All data were analyzed using either unpaired or paired Student's t-test, Pearson's correlation, one-way ANOVA with Tukey's post-hoc test or χ2 test. Data analysis were applied using SPSS version 22.0 (IBM Corp.) and GraphPad Prism version 6.0 (GraphPad Software, Inc.). For all tests, a two-sided P<0.05 was considered to indicate a statistically significant difference.

Results

Metformin inhibits proliferation and colony formation in breast cancer cells

To investigate the effects of metformin on cell proliferation, MCF7 and 4T1 cells were treated with various concentrations (0, 20 and 50 mM) of metformin and cell viability was measured at the indicated times (0–144 h). As shown in Fig. 1A and B, metformin led to a decrease in cell proliferation in a dose- and time-dependent manner in the two cell lines tested. At the maximum concentration of the drug (50 mM), the proliferation of the two cell lines was almost completely blocked at 144 h. Furthermore, metformin significantly inhibited the colony forming efficiency of both cell lines in a dose-dependent manner (Fig. 1C-E). At 20 mM concentration, metformin decreased the overall rate of colony formation of MCF7 and 4T1 cells by >60% compared with untreated cells, while at 50 mM, metformin inhibited colony formation by 100% compared with untreated cells (Fig. 1C-E). These data indicated that metformin effectively inhibited breast cancer cell proliferation in vitro.

Figure 1.

Metformin inhibits proliferation and colony formation, induces G0/G1 cell cycle arrest and decreases cyclin D1 expression in breast cancer cells. Cell proliferation in (A) 4T1 and (B) MCF7 treated with metformin (0, 20 and 50 mM) measured using MTT assay. *P<0.05 vs. control group (0 mM). The number of cell colonies (>50 cells) for (C) 4T1 and (D) MCF7 cells were calculated as: Colonies/500×100. **P<0.01; ***P<0.001. (E) Representative images of cell colony formation. Cell cycle analysis using flow cytometry in (F) 4T1 and (G) MCF7 cells. Proportions of cells in the G0/G1, S or G2/M phases of the cell cycle are indicated. (H) Western blot analysis for cyclin D1 in breast cancer cells treated for 48 h with metformin (0, 20 and 50 mM).

Metformin downregulates cyclin D1 expression and induces G0/G1 cell cycle arrest in breast cancer cells

To further study the effect of metformin on cell cycle progression, the percentage of cells in each respective cell cycle phase was detected by flow cytometry. As shown in Fig. 1F and G, metformin markedly increased the proportion of cells in G0/G1 phase by >10% compared with untreated cells, whereas the number of cells in the S phase was markedly decreased, especially in 4T1 cells. Moreover, cyclin D1 protein expression, a key regular of the G1/S transition, was markedly downregulated in a dose-dependent manner in cells treated with metformin compared with in control cells (Fig. 1H). Overall, these results demonstrated that metformin exerted its antitumor activity by inducing cell cycle arrest.

Metformin inhibits the growth of 4T1 cell xenografts in nude mice

To determine the inhibitory effect of metformin on cell proliferation in vivo, nude mice were subcutaneously injected with 4T1 cells, and treated daily with metformin (250 mg/kg) or saline when the diameter of xenograft tumors reached 4 mm. Mice were sacrificed after 2 weeks and tumors were excised. As shown in Fig. 2A-C, the administration of metformin alone significantly decreased the growth of tumor-cell xenografts in vivo. The H&E-stained slides of paraffin-embedded excised tumors indicated a decrease in tumor cell volume and density in treated mice compared with in untreated mice (Fig. 2D). Furthermore, consistent with the aforementioned results in vitro, a significant decrease in cyclin D1 and PCNA expression was observed in metformin-treated tumors compared with in untreated tumors (Fig. 2D-F). Thus, these results demonstrated that metformin inhibited the growth of breast cancer cell xenografts in nude mice.

Figure 2.

Metformin inhibits breast tumor growth in vivo. (A) Representative images of the excised tumors of untreated and treated groups (n=5 per group). (B) Longitudinal tumor growth curves of 4T1 cell xenografts after metformin treatment. *P<0.05 vs. PBS. (C) Tumor weight of 4T1 cell xenografts. *P<0.05. (D) Representative images of immunohistochemical analysis of 4T1 ×enografts demonstrating staining of HE, PCNA and cyclin D1 in tumor sections from untreated and metformin-treated groups (magnification, ×200). Quantification of differences of (E) PCNA and (F) cyclin D1 expression in metformin-treated and untreated groups ***P<0.001. HE, hematoxylin and eosin; PCNA, proliferating cell nuclear antigen.

Metformin activates AMPK and inhibits COX-2 in vitro and in vivo

The anticancer effects of metformin are mediated via the AMPK signaling pathway (43). Therefore, the present study investigated whether metformin could activate AMPK by measuring the levels of p-AMPK at Thr-172. As expected, treatment of 4T1 and MCF7 cells with metformin significantly increased p-AMPK levels (Fig. 3A) and relative protein levels of p-AMPK/AMPK (Fig. 3B) in a dose-dependent manner. In vivo, significantly increased levels of p-AMPKα were observed in xenograft tumor sections obtained from mice after metformin treatment compared with in those obtained from untreated mice (Fig. 3D). Previously, it has been shown that activation of the AMPK signaling pathway with epigallocatechin-3-gallate (EGCG) abrogates COX-2 expression and PGE2 production in colon cancer cells (44). Thus, the present study studied whether metformin could inhibit COX-2 expression and PGE2 production. The current results revealed that metformin inhibited COX-2 and PGE2 expression in breast cancer cells in a dose- and time-dependent manner (Fig. 3A and C). This was also reflected in the percentage of positively-stained cells in the tissues of mice treated with metformin (Fig. 3D). In summary, these findings strongly suggested that metformin may be a potent inhibitor of the COX-2 signaling pathway and may modulate cell cycle progression to restrain tumor growth.

Figure 3.

Metformin treatment activates AMPKα and inhibits COX-2 expression in breast cancer cells. (A) Western blot analysis of AMPKα, p-AMPKα, PGE2 and COX-2 in cells treated with or without metformin for 48 h. (B) Quantitative analysis of the proportion of p-AMPK/AMPK. *P<0.05 vs. control group (0 mM). (C) Western blot analysis for COX-2 and PGE2 in cells treated with or without metformin. (D) Representative images and quantification of immunohistochemical analysis of COX-2 and p-AMPKα levels in tumor sections obtained from untreated and metformin-treated mice (magnification, ×200). ***P<0.001. AMPK, AMP kinase; COX-2, cyclooxygenase-2; PGE2, prostaglandin E2; p, phosphorylated.

Metformin inhibits the transcription of COX-2

To determine whether metformin transcriptionally regulates COX-2, a pGL3-COX-2 plasmid containing a 2,000-bp region upstream of the human COX-2 promoter was used. The dual luciferase assay indicated that compared with no treatment, the relative COX-2 promoter activity was significantly decreased upon treatment of 4T1 and MCF7 cells with metformin (Fig. 4A and B). Moreover, the mRNA expression levels of COX-2 were significantly decreased upon treatment of both cells with metformin (Fig. 4C and D). These data indicated that metformin inhibited COX-2 transcription.

Figure 4.

Metformin treatment inactivates COX-2 transcription. Relative luciferase activity in (A) 4T1 and (B) MCF7 cells co-transfected with COX-2 promoter-luciferase construct and Renilla luciferase, and treated with metformin (0, 20 and 50 mM). Reverse transcription-quantitative PCR analysis of COX-2 expression in (C) 4T1 and (D) MCF7 cells treated with metformin (0, 20 and 50 mM) for 48 h. *P<0.05, **P<0.01 and ***P<0.001. COX-2. cyclooxygenase-2.

Expression profiles of COX-2 and p-AMPKα in patients with breast cancer

Next, p-AMPKα and COX-2 protein expression was measured in the tissues of 63 cases with invasive breast cancer. p-AMPKα and COX-2 were primarily expressed in the cytoplasm of cells obtained from normal breast and tumor tissues (Fig. 5). Furthermore, downregulation of p-AMPKα and upregulation of COX-2 expression was observed in the tumor tissues compared with in adjacent non-cancerous tissues (Fig. 5A-F). The mean expression values of COX-2 in tumor tissues were significantly increased compared with in normal tissues (1.36±0.97 vs. 0.70±0.61, respectively; Fig. 5E). By contrast, the mean values of p-AMPKα in tumors (0.82±0.84) were significantly lower than in normal tissues (2.37±0.31) (Fig. 5F).

Figure 5.

Expression profiles of COX-2 and p-AMPKα in breast cancer tissues and non-cancerous ductal epithelium. Representative staining of COX-2 in (A) N epithelium and (B) T specimens. (C) Graphical representation of the differences of COX-2 staining in N and T tissues. Representative staining of p-AMPKα in (D) N epithelium and (E) T specimens (magnification, ×400). (F) Graphical representation of the differences of p-AMPKα staining in N and T tissues. Graphical representation of the differences of (G) COX-2 and (H) p-AMPKα staining between stage I/II and stage III/IV. *P<0.05; **P<0.01; ***P<0.001. N, non-neoplastic; T, tumor; p-AMPK, phosphorylated AMP kinase; COX-2, cyclooxygenase-2.

The association of clinicopathological variables with COX-2 and p-AMPKα expression is summarized in Table I. Increased levels of COX-2 were significantly associated with lymphatic metastasis and TNM stage in patients with breast cancer. COX-2 expression was more common in breast tumors with lymphatic metastasis (81.0%) than in those without lymphatic metastasis (42.9%) (P=0.004; Table I). Additionally, COX-2 expression was more common in patients with stage III/IV (90.0%) than in those with stage I/II disease (49.1%) (P=0.017; Table I). Moreover, COX-2 expression was significantly lower in stage I/II tumors (1.40±0.97) compared with in stage III/IV tumors (2.47±0.46) (Fig. 5G). No significant associations were identified between COX-2 expression and other clinicopathological factors, such as age, T stage, and ER, PR, HER2 and p53 status (P>0.05; Table I). Compared with in non-cancerous ductal tissues, p-AMPKα expression was significantly lower in primary tumors (Fig. 5F), but there was no significant association between p-AMPKα and any clinicopathological variable (Table I). However, p-AMPKα expression was significantly higher in stage I/II tumors (0.84±0.81) compared with in stage III/IV tumors (0.45±0.71) (Fig. 5H).

Table I.

Association between COX-2, p-AMPKα and p-4E-BP1 expression and clinicopathologic features in patients with breast cancer (n=63).

Variables	N	COX-2, n (%)	P-value	p-AMPKα, n (%)	P-value	p-4E-BP1, n (%)	P-value
Age, years
<50	29	16 (55.2)	0.955	15 (51.7)	0.923	16 (55.2)	0.596
≥50	34	19 (55.9)		18 (52.9)		21 (61.8)
pT
pT1/2	51	28 (54.9)	0.830	27 (52.9)	0.854	31 (60.9)	0.495
pT3/4	12	7 (58.3)		6 (50.0)		6 (50.0)
pN
No	42	18 (42.9)	0.004	23 (45.1)	0.593	20 (47.6)	0.011
Yes	21	17 (81.0)		10 (47.6)		17 (81.0)
TNM stage
I/II	53	26 (49.1)	0.017	30 (56.6)	0.122	28 (52.8)	0.029
III/IV	10	9 (90.0)		3 (30.0)		9 (90.0)
ER
+	34	16 (47.1)	0.955	20 (58.8)	0.268	16 (47.1)	0.596
−	29	19 (65.5)		13 (44.8)		21 (72.4)
PR
+	32	20 (62.5)	0.260	18 (56.3)	0.532	19 (59.4)	0.685
−	31	15 (48.4)		15 (48.4)		18 (58.1)
Her2
+	20	14 (70.0)	0.116	10 (50.0)	0.796	15 (75.0)	0.074
−	43	21 (48.8)		23 (53.5)		22 (51.2)
p53
+	26	18 (69.2)	0.057	15 (57.7)	0.479	19 (73.1)	0.156
−	37	17 (45.9)		18 (48.6)		18 (48.6)
Total	63	35 (55.6)		33 (52.4)		37 (58.7)

pT, pathological assessment of primary tumor; pN, pathological assessment of regional lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor; COX-2, cyclooxyeganse-2; p, phosphorylated; AMPK, AMP kinase; 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1.

Metformin inhibits phosphorylation of 4E-BP1 in vitro and in vivo

The activation of AMPK inhibits the mTOR signaling pathway and decreases phosphorylation of S6 kinase (S6K) in breast cancer (45). Thus, the specific effects of metformin on 4E-BP1 (Thr-37/46), another downstream target of mTOR, were examined in the present study. As shown in Fig. 6A-D, the phosphorylation levels of 4E-BP1 and relative protein levels of p-AMPK/AMPK decreased in a dose- and time-dependent manner following metformin treatment. The p-4E-BP1 levels were significantly decreased in excised mouse tumors after treatment with metformin (Fig. 6E). The current results are consistent with a previous study that has demonstrated that metformin inhibits tumor growth mainly via the AMPK/mTOR signaling pathway (46).

Figure 6.

Metformin treatment inhibits phosphorylation of 4E-BP1. (A) Western blot analysis of 4E-BP1 and p-4E-BP1 in 4T1 cells treated with metformin (0, 20 and 50 mM) for 48 h and (B) quantification of p-4E-BP1/4E-BP1 ratio. (C) Western blot analysis of 4E-BP1 and p-4E-BP1 in 4T1 cells treated with metformin (20 mM) for the indicated time periods and (D) quantification of p-4E-BP1/4E-BP1 ratio. *P<0.05 vs. control group. (E) Representative images (magnification, ×400) and quantification of immunostaining for p-4E-BP1 in tumor sections from metformin-treated and control mice. ***P<0.001. (F) Representative staining of COX-2 and p-4E-BP1 in cancer tissues from the same patient (left, ×10; right, ×400). (G) Association between COX-2 and p-4E-BP1 staining and (H) correlation between COX-2 and p-4E-BP1 expression. (I) Diagrammatic sketch showing that activation of AMPK by metformin leads to inhibition of the mTOR signaling pathway and COX-2 expression, which results in decreased cell proliferation and tumor growth. COX-2, cyclooxyeganse-2; p, phosphorylated; AMPK, AMP kinase; 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; PGE2, prostaglandin E2.

Subsequently, the expression profile of p-4E-BP1 in breast cancer specimens and the correlation between the levels of p-4E-BP1 and COX-2 were evaluated. p-4E-BP1 staining was preferentially localized to the cytoplasm and was markedly increased in tumor tissues compared with in adjacent non-cancerous breast epithelium (Fig. 6F). Of the 63 tumors, 37 (58.7%) exhibited high p-4E-BP1 levels, which were significantly associated with lymphatic metastasis and TNM stage (Table I). Co-expression of COX-2 and p-4E-BP1 was observed in 32 (50.8%) tumors, while 23 (36.5%) showed no expression of either COX-2 or p-4E-BP1 (χ2=34.738; P<0.001; Fig. 6G). Pearson correlation analysis revealed that COX-2 expression was positively correlated with p-4E-BP1 expression among the 63 breast tumors (r=0.743; P<0.001; Fig. 6H). Furthermore, COX-2 expression co-localized with p-4E BP1 levels in the same specimens (Fig. 6F). Overall, the current data suggested that activation of AMPK by metformin may lead to inhibition of the mTOR signaling pathway and COX-2 expression, resulting in decreased cell proliferation and tumor growth (Fig. 6I).

Discussion

The present study aimed to explore a novel anticancer mechanism of the anti-diabetic drug metformin. Metformin is known to exert its antitumor effects by activating AMPK and inhibiting mTOR-mediated phosphorylation of S6K1 and 4E-BP1 in the AMPK/mTOR signaling pathway (47). The current study described a novel role of metformin by demonstrating that metformin significantly suppressed cell proliferation in vitro and decreased tumor growth in vivo by targeting the COX-2 and AMPK/mTOR signaling pathways. Treatment with metformin alone significantly decreased the expression levels of COX-2 and p-4E-BP1 in breast cancer cells. Furthermore, COX-2 and p-4E-BP1 were frequently upregulated and strongly associated with nodal metastasis and advanced disease stage, implicating their dual-role as predictive biomarkers and therapeutic targets in breast cancer.

Clinical and epidemiological studies have demonstrated that compared with individuals without diabetes, the relative risk of progression to breast cancer is increased in patients with type 2 DM, and treatment with metformin decreases the relative risk for breast cancer and cancer-associated mortality in diabetic patients (48–50). Pre-clinical studies have indicated that the majority of breast cancer cell lines show sensitivity to metformin treatment (17,20). The present data further confirmed that metformin was able to decrease cell viability in a dose- and time-dependent manner, and inhibited the rate of colony formation in breast cancer cells. The highest concentration of metformin (50 mM) completely blocked the proliferation rate of breast cancer cells. These anticancer effects of metformin, as evidenced by the increased proportion of cells in G0/G1 phase and decreased cyclin D1 expression, were associated with cell cycle arrest. Moreover, tumors excised from metformin-treated mice exhibited significantly slower growth and lower tumor volume than those from mice not treated with metformin. Moreover, metformin treatment altered the morphology of cancer cells, as demonstrated by significantly smaller cell types and larger intervals between cells in the xenograft tissues of metformin-treated mice than those in control mice. These changes may be due to a metabolic response to metformin toxicity. Further immunohistochemical analysis confirmed the low proliferation index (as indicated by PCNA) and low levels of cyclin D1 in the metformin-treated mice compared with in control mice (16,17).

Furthermore, consistent with previous studies (51–53), the present study demonstrated that metformin alone was sufficient to activate AMPK and inhibit p-4E-BP1 and cyclin D1. Metformin decreases PGE2 synthesis by activating AMPK (54), and COX-2 is the key enzyme in PGE2 synthesis (55). Therefore, it was speculated that metformin may serve an anticancer role through the AMPK-mediated COX-2 signaling pathway. To the best of our knowledge, the present study was the first to demonstrate that treatment with metformin alone significantly decreased COX-2 protein expression in a dose- and time-dependent manner in vitro and in vivo. COX-2 is undetectable in most normal tissues and accumulates in activated macrophages and other cells at sites of inflammation (56). A previous study has indicated that COX-2 expression is upregulated in various types of cancer, including gastric, colorectal and lung cancer, and serves a crucial role in tumorigenesis (57). AMPK activation by selenium and EGCG abrogate COX-2 expression in colon cancer cells (44). Similar results were observed in the present study in breast cancer cells upon treatment with another AMPK activator, metformin. The increase in metformin concentrations significantly increased AMPK activity and decreased COX-2 expression. Moreover, continued use of metformin resulted in gradual reduction in COX-2 expression, including at the mRNA level. Additionally, the inhibition of the activity of the pGL3-COX-2-promoter suggested that AMPK activation abolished the transactivation of COX-2. Overall, the current results suggested that metformin regulated COX-2 production at both the transcriptional and post-transcriptional levels, and identified a potential association between AMPK activation by metformin and inhibition of inflammatory events.

AMPK and COX-2 expression is well-studied in human solid cancer tissues, such as gastric, colorectal and ovarian cancer (58–61). p-AMPK expression is decreased in ~90% of patients with breast cancer and is significantly associated with higher histological grade and axillary node metastasis (62). In accordance with the aforementioned studies, the present study demonstrated that p-AMPKα expression was strong in normal breast epithelium and weak in primary breast cancer tissues. The levels of p-AMPKα decreased with disease progression, although no significant association was observed with clinicopathological factors due to the relatively small cohort. Given the association between AMPK and COX-2, it is plausible that decreased p-AMPKα levels may be associated with increased COX-2 expression. The current data indicated that COX-2 expression was increased in primary breast cancer specimens compared with in normal breast epithelium, consistent with previous studies (24,25). Additionally, COX-2 positivity was significantly associated with high histological grade and lymph node metastasis. Enhanced COX-2 expression was frequently associated with decreased levels of p-AMPKα, although this association was not significant due to the relatively small number of cases in the present study. These data further suggest the importance of the AMPK/COX-2 axis in breast cancer development and progression.

Furthermore, a previous study has revealed that metformin exerts anticancer effects by activating AMPK, which results in inhibition of mTOR kinase and decreased S6K1 activity (63). Consistent with a previous study (18), the present study indicated that metformin also suppressed another mTOR downstream effector, 4E-BP1, thus making it a particularly attractive molecule for investigation in breast cancer. The current data offer a novel mechanistic insight into the potential use of metformin for treatment of breast cancer. Previous studies have demonstrated that p-4E-BP1 levels are associated with malignant progression and adverse prognosis in breast cancer (64–66). The current data revealed that p-4E-BP1 levels were significantly elevated in the majority of breast cancer cases, and p-4E-BP1 positivity was common in cases with nodal metastasis and advanced disease stage. The AMPK/mTOR axis is a well-known effective therapeutic target in metabolic syndromes and cancer, while COX-2 is an established therapeutic target in inflammatory diseases and cancer (67–70). Therefore, cross-talk between the AMPK/mTOR and COX-2 signaling pathways can be expected in cancer pathophysiology. The present results indicated that AMPK activation by metformin decreased both p-4E-BP1 and COX-2 expression in breast cancer cells, which supports the hypothesis that the two pathways are connected. Moreover, immunostaining revealed a close correlation between the levels of these proteins. Thus, p-4E-BP1 and COX-2 may have potential roles as predictive markers and therapeutic targets in breast cancer.

To the best of our knowledge, the present study was the first to demonstrate that metformin activated AMPK and suppressed COX-2 expression to inhibit breast cancer cell proliferation. The current findings are supported by clinical research published by Jiralerspong et al (71), who reported a 3-fold greater complete pathologic response in diabetic patients with breast tumors receiving metformin and neoadjuvant chemotherapy than in those with breast tumors not receiving metformin. Therefore, metformin co-treatment with conventional therapy may serve as a successful therapeutic strategy in the prevention of cancer recurrence and improvement of long-term survival.

In conclusion, the present study revealed the novel finding that metformin activated AMPK, which suppressed the production of COX-2 and abrogated breast cancer cell proliferation. Thus, metformin may serve as a potential therapeutic drug for the treatment of patients with breast cancer, and further studies should be performed to investigate how it may be used in cancer therapy alone or in combination with other antitumor drugs.